Nininger Medical

Nininger Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Nininger Medical is an early-stage, pre-revenue medical device startup focused on innovative solutions for structural heart failure. Founded in 2019, the company is developing patent-pending transcatheter heart valve technology, indicating a minimally invasive therapeutic approach. Its initial development has been funded by an SBIR grant from the National Science Foundation, awarded in December 2020. The company operates in the large and growing structural heart disease market but remains in a pre-clinical or early R&D stage with no disclosed pipeline programs or leadership team.

Cardiovascular DiseaseStructural Heart DiseaseHeart Failure

Technology Platform

Patent-pending technology for transcatheter heart valve therapies, focused on minimally invasive treatment of structural heart failure. Specific mechanism undisclosed.

Opportunities

The global structural heart device market is large and growing, with significant unmet needs in transcatheter mitral and tricuspid valve therapies.
A successful, differentiated technology could address a multi-billion dollar market segment and attract acquisition interest from major medtech companies.

Risk Factors

The company is at an extremely early, pre-clinical stage with minimal funding, facing high technical risk of device failure and financial risk of being unable to secure the substantial capital required for development.
It also operates in a market dominated by large, well-resourced competitors.

Competitive Landscape

The transcatheter heart valve market is highly competitive, dominated by large players like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific. These companies have extensive R&D budgets, commercial networks, and established clinical data, creating a high barrier to entry for a small startup like Nininger Medical.